POTENTIAL THERAPEUTIC APPROACHES TO THE TREATMENT OR PREVENTION OF DIABETIC NEUROPATHY - EVIDENCE FROM EXPERIMENTAL STUDIES

被引:100
作者
CAMERON, NE
COTTER, MA
机构
[1] Department of Biomedical Sciences, University of Aberdeen
关键词
DIABETES-MELLITUS; NEUROPATHY; NERVE BLOOD FLOW; VASODILATOR TREATMENT; POLYOL PATHWAY; OXIDATIVE STRESS; ADVANCED GLYCATION; TROPHIC FACTORS;
D O I
10.1111/j.1464-5491.1993.tb00131.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recent investigations using experimental models of diabetes mellitus have emphasized the importance of impaired blood flow for the development of nerve dysfunction. Other observations suggest that this may also be the case for patients. A number of studies have revealed that several types of vasodilators can prevent or successfully treat early conduction abnormalities in diabetic rodents. These include alpha1-adrenoreceptor antagonists, calcium channel blockers, agents that inhibit the renin-angiotensin system, and vasomodulator prostanoids. Other treatments applied to animal models, such as omega-6 essential fatty acids, aldose reductase inhibitors, aminoguanidine which prevents the formation of advanced glycation end-products, and anti-oxidants all appear to have vascular-related effects that lead to improvements in nerve conduction. These findings suggest that endothelial dysfunction and oxidative stress could be important factors in the aetiology of diabetic neuropathy. Studies have also focused on deficits in axon growth and regeneration, their relation to impaired neuronal synthesis and transport of growth-related chemicals, and neuronotrophic abnormalities. Taken together, the data give rise to the notion that an optimal therapeutic strategy could consist of improving the microenvironment of damaged nerve fibres by manipulating nerve blood flow while concurrently encouraging repair with trophic agents.
引用
收藏
页码:593 / 605
页数:13
相关论文
共 162 条
[51]  
Kappelle AC, Bravenboer B., Traber J., Erkelens DW, Gispen WH., The Ca<sup>2 4</sup> antagonist nimodipine counteracts the onset of an experimental neuropathy in streptozotocin induced diabetic rats, Neurosci Res Commun, 10, pp. 95-104, (1992)
[52]  
Robertson S., Cameron NE, Cotter MA., The effect of the calcium antagonist nifedipine on somatic nerve function in streptozotocin‐diabetic rats, Diabetologia, 35, pp. 1113-1117, (1992)
[53]  
Bjork S., Aurell M., Diabetes mellitus, the renin‐angiotensin system, and angiotensin‐converting enzyme inhibition, Nephron, 55, pp. 10-20, (1990)
[54]  
Sullivan PA, Gonggrijp H., Crowley MJ, Ferriss JB, O'Sullivan DJ., Plasma angiotensin II and the control of diabetes mellitus, Clin Endocrinol, 13, pp. 387-392, (1980)
[55]  
O'Hare JA, Ferriss JB, Twomey BM, Gonggrijp H., O'Sullivan DJ., Changes in blood pressure, body fluids, circulating angiotensin II and aldosterone, with improved diabetic control, Clinical Science, 63, pp. 415-418, (1982)
[56]  
Wilkes BM., Reduced glomerular angiotensin II receptor density in diabetes mellitus in rats: time course and mechanism, Endocrinology, 120, pp. 1291-1298, (1987)
[57]  
Connell JMC, Ding Y., Fisher BM, Frier BM, Semple PF., Reduced number of angiotensin II receptors on platelets in insulin‐dependent diabetes, Clin Sci, 71, pp. 217-220, (1986)
[58]  
Hallab M., Bled F., Ebran JM, Suraniti S., Girault A., Fressinaud P., Et al., Elevated serum angiotensin I converting enzyme activity in type 1, insulin‐dependent diabetic subjects with persistant microalbuminuria, Acta Diabetologica, 29, pp. 82-85, (1992)
[59]  
Dzau VJ, Gibbons GH, Pratt RE., Molecular mechanism of vascular renin‐angiotensin system in myointimal hyperplasia, Hypertension, 18, pp. 100-105, (1992)
[60]  
Cameron NE, Cotter MA, Robertson S., Rapid reversal of a motor nerve conduction deficit in streptozotocin‐diabetic rats by the angiotensin converting enzyme inhibitor lisinopril, Acta Diabetologica, 30, (1993)